Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
Source: View publication →
In younger patients with mantle cell lymphoma, adding ibrutinib to frontline induction and maintenance significantly improved failure-free survival, and standard ASCT was not superior to an ibrutinib-based regimen without transplantation.
Key Findings
Study Design
Study Limitations
Clinical Significance
The TRIANGLE trial represents a major paradigm shift in the frontline management of younger, transplant-eligible patients with mantle cell lymphoma (MCL). By proving that the incorporation of ibrutinib improves failure-free survival—and crucially demonstrating that traditional toxic high-dose therapy (ASCT) is not superior to an ibrutinib-based regimen without transplantation—the trial paves the way toward minimizing or entirely omitting intensive chemotherapy consolidation in favor of targeted BTK-inhibitor therapy.
Historical Context
For roughly two decades, the standard of care for younger, medically fit patients with MCL was intensive cytarabine-containing immunochemotherapy induction followed by high-dose therapy and ASCT, plus rituximab maintenance. While this aggressive approach prolonged remissions, patients inevitably relapsed and faced significant short- and long-term toxicities. Following the dramatic success of BTK inhibitors like ibrutinib in the relapsed/refractory setting, the European MCL Network initiated the TRIANGLE trial to test whether moving targeted therapy to the frontline could improve outcomes and challenge the historical necessity of ASCT consolidation.
Guided Discussion
High-yield insights from every perspective
Mantle cell lymphoma is driven by a specific chromosomal translocation and overexpression of a cell cycle regulator. How does the addition of ibrutinib, as used in the TRIANGLE trial, mechanistically target the disease, and what is the underlying cytogenetic hallmark it operates alongside?
Key Response
Tests foundational knowledge of the t(11;14) translocation causing Cyclin D1 overexpression, and the mechanism of ibrutinib as an irreversible inhibitor of Bruton Tyrosine Kinase (BTK) in the B-cell receptor signaling pathway.
Historically, high-dose cytarabine-containing induction followed by ASCT was the standard for young, fit MCL patients. Based on the TRIANGLE trial results, how might you counsel a 55-year-old newly diagnosed MCL patient regarding the necessity and potential risks of ASCT compared to an ibrutinib-inclusive regimen without transplant?
Key Response
Encourages residents to translate trial data into practical patient counseling, weighing the traditional ASCT paradigm (infectious and cytopenic risks) against the novel continuous BTK inhibitor approach which demonstrated superior/non-inferior failure-free survival.
The TRIANGLE trial suggests an ibrutinib-based induction and maintenance regimen without ASCT is highly effective. However, how should high-risk molecular features, such as TP53 mutations, influence the decision to omit ASCT in favor of BTKi therapy, and what specific long-term toxicities must be monitored during prolonged ibrutinib maintenance?
Key Response
Requires fellows to consider subgroup nuances like TP53-mutated MCL (where ASCT traditionally fails, making BTKi or CAR-T more appealing but still challenging) and manage class-specific BTKi adverse events like atrial fibrillation, hypertension, and bleeding risk during continuous maintenance.
If the TRIANGLE data leads to the widespread omission of ASCT in frontline MCL management in favor of continuous BTK inhibition, how does this paradigm shift impact our sequencing of later-line therapies, particularly regarding the use of CAR-T cell therapy or non-covalent BTK inhibitors upon first relapse?
Key Response
Challenges attendings to think longitudinally about survivorship and resistance. Moving BTK inhibitors to the frontline eliminates the standard second-line option, accelerating the need for CAR-T (e.g., brexucabtagene autoleucel), bispecific antibodies, or reversible BTKis (pirtobrutinib) much earlier in the disease course.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The TRIANGLE trial utilized a complex three-arm design to test both the addition of ibrutinib to ASCT and the substitution of ASCT with ibrutinib. What are the statistical challenges and multiplicity considerations in powering a trial to establish both superiority of combination therapy and non-inferiority/superiority against standard ASCT, and how does the open-label nature affect failure-free survival endpoints?
Key Response
Evaluates understanding of hierarchical testing, alpha spending in multi-arm trials, and the potential bias in investigator-assessed FFS in an open-label setting, particularly regarding subjective decisions to initiate subsequent therapy.
As a reviewer, a major critique of early readouts in indolent or moderately aggressive lymphomas is the maturity of the data. Given the continuous nature of ibrutinib maintenance versus a one-time ASCT, how does the current median follow-up time in the TRIANGLE trial potentially skew the failure-free survival curves, and what confounding effect does post-protocol crossover have on overall survival analyses?
Key Response
A seasoned editor would flag that continuous maintenance therapy might delay progression early on, while ASCT might offer a longer plateau later. Short follow-up favors the continuous therapy arm, and access to BTKi post-ASCT relapse complicates the ultimate overall survival analysis.
Current NCCN and ESMO guidelines recommend intensive induction followed by ASCT for young, fit patients with MCL. Does the TRIANGLE trial provide sufficient Level 1 evidence to formally remove ASCT from the preferred frontline algorithm entirely, or should ibrutinib without ASCT be listed as a Category 1 alternative pending longer-term overall survival and safety data?
Key Response
Guideline committees must decide if the standard of care is completely replaced or if a new option is added. Given FFS benefits but pending long-term OS and continuous-therapy toxicity data, adding the Ibrutinib arm (without ASCT) as a co-preferred Category 1 option rather than entirely discarding ASCT is a critical debate for guideline updates.
Clinical Landscape
Noteworthy Related Trials
MCL Younger Trial
Tested
Alternating R-CHOP and R-DHAP followed by ASCT
Population
Previously untreated patients with mantle cell lymphoma aged 65 years or younger
Comparator
6 courses of R-CHOP followed by ASCT
Endpoint
Time to treatment failure (TTF)
LyMa Trial
Tested
Rituximab maintenance every 2 months for 3 years
Population
Young, previously untreated MCL patients who responded to induction and ASCT
Comparator
Observation
Endpoint
Event-free survival (EFS)
SHINE Trial
Tested
Ibrutinib plus bendamustine-rituximab and rituximab maintenance
Population
Older patients (aged 65 or older) with previously untreated mantle-cell lymphoma
Comparator
Placebo plus bendamustine-rituximab and rituximab maintenance
Endpoint
Progression-free survival (PFS)
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis